Related Experiment Video

Updated: Jun 24, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

Recent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis

Kristen Hayward1, Carol A Wallace

  • 1Division of Rheumatology, University of Washington School of Medicine, Seattle Children's Hospital, 4800 Sandpoint Way, NE MS R-5420, Seattle, WA 98105, USA. Kristen.hayward@seattlechildrens.org

Arthritis Research & Therapy
|March 18, 2009
PubMed

Insights

Early aggressive treatment is key for juvenile idiopathic arthritis (JIA) to improve long-term outcomes. Novel biologic therapies offer new hope for managing this common childhood autoimmune disease.

Area of Science:

  • Pediatric Rheumatology
  • Immunology
  • Autoimmune Diseases

Background:

  • Juvenile idiopathic arthritis (JIA) is the most prevalent autoimmune-autoinflammatory condition in children, affecting about 1 in 1,000. Despite treatment advances, JIA often persists chronically.
  • Emerging evidence highlights the critical role of early disease control in shaping JIA's long-term prognosis and disease trajectory.
  • The concept of a 'therapeutic window of opportunity' emphasizes the need for prompt, intensive interventions in newly diagnosed JIA patients.

Purpose of the Study:

  • To review recent advancements in the medical management of JIA in children.
  • To provide insights into novel and emerging therapeutic strategies for JIA.
  • To underscore the significance of early and aggressive treatment approaches.

Main Methods:

  • Literature review of recent developments in JIA treatment.
  • Analysis of current and emerging therapeutic agents for pediatric JIA.
  • Synthesis of evidence regarding the impact of early disease control.

Main Results:

  • The availability of biologic therapeutics for JIA has significantly expanded.
  • Early aggressive treatment strategies are crucial for optimizing outcomes in JIA.
  • New therapeutic avenues are continually being explored for JIA management.

Conclusions:

  • Prompt and intensive treatment at disease onset is vital for improving long-term outcomes in JIA.
  • The expanding array of biologic therapies offers improved management options for children with JIA.
  • Continued research into emerging therapies holds promise for future JIA treatment.

Related Concept Videos

Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...